A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-415S1 in Patients With Advanced Malignant Solid Tumor
Latest Information Update: 24 Jul 2023
At a glance
- Drugs HMPL-415S1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors HUTCHMED
- 10 Jul 2023 According to a HUTCHMED Media Release, The leading principal investigators are Dr. Tianshu Liu of Zhongshan Hospital Fudan University and Dr. Nong Yang of Hunan Cancer Hospital.
- 10 Jul 2023 Status changed from not yet recruiting to recruiting.
- 10 Jul 2023 According to a HUTCHMED Media Release, the first patient has been dosed on July 6, 2023.